Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3D Systems Reports Fourth Quarter and Full Year 2024 Financial Results

In This Article:

3D Systems Inc.
3D Systems Inc.

ROCK HILL, S.C., March 26, 2025 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2024.

  • Full-year 2024 revenue of $440 million, above lower end of guidance range, inclusive of a $9 million revenue reduction in Q4 driven by a change in accounting estimates for Regenerative Medicine program milestone recognition. This change in estimate is related to the now anticipated use of pre-clinical human decedent testing, successfully demonstrated by our partner, United Therapeutics, which led to refinement of the milestone technical criteria.

  • Continued reduction in operating expenses in Q4 reflecting the company’s focus on cost savings and efficiency improvements.

  • Announcement of a new cost reduction initiative expected to deliver over $50 million in incremental annualized savings related to actions taken throughout 2025 and the first-half 2026.

  • All regulatory approvals have been obtained for sale of Geomagic software platform, with a sale price of $123 million and targeted close in early April.

  • Balance sheet cash and cash equivalents of $171 million as of December 31, 2024. Proceeds from Geomagic sale to further strengthen balance sheet in Q2.

  • Normalizing for divestiture, 2025 full-year forecast reflects return to flat to modest top line organic growth with progressive cost reductions strengthening EBITDA performance throughout the year. Target is to exit 2025 at positive adjusted-EBITDA levels, with continuing momentum in 2026.

 

 

Three Months Ended
December 31,

 

Year Ended
December 31,

 

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

(in millions, expect per share data)

 

(unaudited)

 

(unaudited)

 

 

 

 

Revenue

 

$

111.0

 

 

$

114.8

 

 

$

440.1

 

 

$

488.1

 

Gross profit

 

$

34.4

 

 

$

44.0

 

 

$

164.2

 

 

$

196.4

 

Gross profit margin

 

 

31.0

%

 

 

38.3

%

 

 

37.3

%

 

 

40.2

%

Operating expense

 

$

64.8

 

 

$

371.3

 

 

$

441.6

 

 

$

602.4

 

Operating loss

 

$

(30.4

)

 

$

(327.3

)

 

$

(277.4

)

 

$

(406.0

)

Net loss attributable to 3D Systems Corporation

 

$

(33.7

)

 

$

(292.7

)

 

$

(255.6

)

 

$

(362.7

)

Diluted loss per share

 

$

(0.25

)

 

$

(2.25

)

 

$

(1.94

)

 

$

(2.79

)

 

 

 

 

 

 

 

 

 

Non-GAAP measures for year-over-year comparisons (1)

 

 

 

 

 

 

Non-GAAP gross profit margin

 

 

31.3

%

 

 

39.8

%

 

 

37.4

%

 

 

40.6

%

Non-GAAP operating expense

 

$

58.4

 

 

$

65.4

 

 

$

250.3

 

 

$

246.0

 

Adjusted EBITDA

 

$

(19.1

)

 

$

(14.0

)

 

$

(66.4

)

 

$

(26.3

)

Non-GAAP diluted loss per share

 

$

(0.19

)

 

$

(0.13

)

 

$

(0.62

)

 

$

(0.28

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) See “Presentation of Information in this Press Release” below for a description, and the Appendix for the reconciliation of non-GAAP measurements to the most closely comparable GAAP measure.

 

Summary Comments on Results

“While 2024 was a challenging year for sales, reflecting weak customer capex spending on new manufacturing plant capacity through the first three quarters, we were pleased to see a healthy uptick in the sale of new industrial printer systems and global services in the fourth quarter,” said Dr. Jeffrey Graves, president & CEO of 3D Systems. “In addition, with the largest installed base in the additive manufacturing industry, we were pleased to see a return to healthy consumable sales across most markets, reflecting higher utilization rates for existing machines. These positive changes in our core business units were unfortunately masked by the impact of an accounting estimate change in our Regenerative Medicine program related to refinement of technical acceptance criteria associated with a potential change in testing methodology for printed human lungs, which are the focus of this program. This estimate change relates to the incorporation of in vivo human decedent testing protocols, which have recently been successfully demonstrated by our partner, United Therapeutics. While this accounting estimate change was not originally contemplated in our 2024 guidance, I am pleased that our core businesses still delivered within the full-year revenue range communicated in our prior forecast, and that the market showed signs of strengthening in the fourth quarter.”